Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit

Completed

Conditions studied: Gram-negative Bacterial Infections

In brief

The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) \[measured as defined daily doses per 1000 patient days\]; physician acceptance of piperacillin as part of a streamlining program \[measured as successful occurrences of the use of piperacillin as streamlining therapy\]; changes in susceptibility patterns of broad spectrum antibiotics \[measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics\]; and outcome of patients treated with streamlined therapy.

Key facts

Study ID

NCT00177814

Run by

University of Pittsburgh

People needed

1000

Starts

2005-09-01

Expected to finish

2017-06-01

Last updated by the study team

2018-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with Gram negative infections treated with piperacillin/tazobactam and/or piperacillin

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.